Drugs / Pimonidazole

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT03718650 Apr 2021 → Apr 2022 malignant pancreatic neoplasm, pancreatic exocrine neoplasm H. Lee Moffitt Cancer Center and Research Institute Withdrawn No outcome recorded
Phase 11 trial
Phase 1 NCT03410420 Sep 2018 → Sep 2025 thoracic aortic aneurysm Thomas Gleason Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03181035 Jan 2018 → Sep 2024 tongue cancer Sunnybrook Health Sciences Centre Suspended No outcome recorded
Phase 23 trials
Phase 2 NCT02414048 Apr 2015 → Oct 2022 head and neck cancer Marius Gustav Bredell Unknown No outcome recorded
Phase 2 NCT02061007 Oct 2014 → Feb 2016 melanoma, skin cancer H. Lee Moffitt Cancer Center and Research Institute Withdrawn No outcome recorded
Phase 2 NCT00374517 Sep 2006 → Feb 2010 pulmonary tuberculosis National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase not applicable1 trial
NCT03418818 Mar 2018 → Oct 2028 expected sarcoma University Health Network, Toronto Active not recruiting No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01992042 Background Feb 2014 → Oct 2016 prostate cancer University Health Network, Toronto Completed No outcome recorded
Phase not applicable1 trial
NCT02095249 Background Sep 2014 → Jan 2028 expected prostate cancer University Health Network, Toronto Active not recruiting No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Pimonidazole ClinicalTrials.gov intervention name — accepted as the source's own label NCT02061007
8

NCT02095249

NCT03410420

NCT03418818

NCT03718650

NCT03181035

NCT00374517

NCT01992042

NCT02414048

Known as Hypoxyprobe-1 “This is a prospective study designed to determine the safety and value of Hypoxyprobe-1 (pimonidazole hydrochloride (-HCl)) to detect levels of tissue hypoxia in patients...” NCT03410420
1

“Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).” NCT02061007

Known as NSC-380540 ChEMBL registry synonym — accepted as the source's own label CHEMBL58752
Known as PD 126675 ChEMBL registry synonym — accepted as the source's own label CHEMBL58752
Known as Pimonidazol ChEMBL registry synonym — accepted as the source's own label CHEMBL58752
Known as Pimonidazole hydrochloride “This is a prospective study designed to determine the safety and value of Hypoxyprobe-1 (pimonidazole hydrochloride (-HCl)) to detect levels of tissue hypoxia in patients...” NCT03410420
Known as pimonidazole hydrochloride (HCl) “a substance called pimonidazole hydrochloride (HCl) it builds up specifically in hypoxic areas” NCT03181035
Known as pimonidazole-HCl “This pilot study will use pimonidazole-HCl, a compound that is retained by hypoxic cells and that has been used for detection of tissue hypoxia in human since the early 2000s.” NCT03410420
1

“a single dose of oral pimonidazole-HCl before having surgery to remove their cancer” NCT03181035

Known as RO 03-8799 ChEMBL registry synonym — accepted as the source's own label CHEMBL58752
Modality Diagnostic / imaging agent “using an in vivo hypoxia-imaging marker, pimonidazole hydrochloride” NCT00374517
Route Intravenous “Infusion of pimonidazole through a vein in the arm 24 hours before surgery.” NCT00374517